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INTRODUCTION
It remains unclear whether cholesteatomatous epithelium
is normal tissue merely in the wrong place or pathologic tissue
with qualitative changes. Cytokeratins (CK) are known as the
intermediate filament proteins of epithelial origin, and they
comprise a family of at least 19 polypeptides. Each pair of
acidic and basic CK is assembled into a 10-nm filament. The
pattern of CK expression is affected only, if at all, by neoplasia
(1) and some proliferative epidermal diseases including psori-
asis, aural cholesteatoma, as well as other epithelial disorders
(2-10).
Mongolian gerbils have a propensity for the development of
aural cholesteatomas. Cholesteatomas were not only found to
develop spontaneously with aging, but experimental cholest-
eatomas can also be induced by external auditory canal ligation
(ECL) (11, 12). Induced cholesteatomas progressively enlarge
to an advanced stage of cholesteatoma over time. Using this
animal model, CK expression pattern can be investigated in
various clinical stages of cholesteatoma. As patterns of CK
expression indicate the state of keratinocyte proliferation, migra-
tion, and differentiation, this study might shed some insight
into the pathogenesis of cholesteatoma.
In the present study, we investigated on the CK immuno-
expression at various epithelial sites, i.e., the external audito-
ry meatus, the tympanic membrane, and the middle ear, in
various stages of gerbilline cholesteatomas of ECL model.
MATERIALS AND METHODS
Ligation of the external auditory canal
Twenty-eight normal mongolian gerbils (60-90 days old),
Meriones unguiculatus, underwent the procedures and postop-
erative care. The procedures were performed in accordance
with the PHS policy on Humane Care and Use of Laboratory
Animals, the NIH Guide for the Care and Use of Laboratory
Animals, and the Animal Care and the Animal Welfare Act
(7 U.S.C. et seq); the animal use protocol was approved by the
Institutional Animal Care and Use Committee (IACUC) of
the University of California, Davis. Each animal was adminis-
tered an intraperitoneal injection of ketamine HCl (Ketaset
�,
50  g/g)/xylazine hydrochloride (Rompun
�, 12.5  g/g)
mixture for anesthesia. Under the operating microscope, the
external auditory canal (EAC) and the tympanic membrane
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Expression Patterns of Cytokeratins in Cholesteatomas: 
Evidence of Increased Migration and Proliferation
Aural cholesteatoma is characterized by invading squamous epithelia with altered
growth properties. Cytokeratin (CK) expression is affected in epidermal proliferative
diseases and represents the alterations of keratinocyte proliferation, differentiation,
and migration. In the present study, the intensity of CK immuno-expression was
determined, using densitometry at various sites in experimental cholesteatoma
in order to characterize changes of keratinocytes. With cholesteatoma formation,
CK4, a marker for non-keratinizing epithelia, increased in the suprabasal layers
of the annular external auditory canal (EAC) and at the pars tensa indicating an
altered differentiation and migration of keratinocytes. CK5/6, a marker of keratinizing
squamous epithelium, increased only at the pars tensa of the tympanic membrane,
indicating basal keratinocyte hyperplasia. CK1/10 increased in the suprabasal
layer at the annular EAC, and at the peripheral pars tensa, indicating increased
terminal differentiation of keratinocytes. CK13/16, markers of differentiation and
hyperproliferation, increased in suprabasal layer of the EAC, and at the peripheral
pars tensa. However, it decreased in the basal layer of the EAC, indicating hyper-
proliferation and migration of keratinocytes. The findings of this study support the
basal cell hyperplasia hypotheses for the pathogenesis of aural cholesteatoma,
with regard to hyperproliferation, migration, and an altered differentiation of ker-
atinocytes.
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(TM) were examined to exclude spontaneous cholesteatoma
formation prior to surgery. An induction method of canal type
cholesteatoma was followed as described in previous studies
(11, 12). Ligation of the EAC was performed on the right ear,
and the left ear was assigned as a control. Following surgery,
the TM and the EAC of the left side were regularly examined
to exclude spontaneous cholesteatoma formation. 
Histopathologic preparation
Twenty-eight temporal bone specimen (56 external/middle
ears) were processed for histopathologic examination. They
were divided into seven groups by the time intervals follow-
ing the surgery: 3 days, 1, 2, 4, 8, 12 weeks, and 1 yr. The
animals were euthanized and transcardially perfused with 10%
formalin solution in phosphate buffered saline. And then, the
bullae were removed en bloc, immersed in the same perfu-
sion fixative for 48 hr, and decalcified in 1.35 N hydrochloric
acid with 0.003 M chelating agent (Cal-X
�), Fisher Scientific
Products) for 24 hr. Following decalcification, specimens were
dehydrated, embedded in paraffin, and sectioned to 8  m in
thickness, along the superior/inferior axis through the EAC
and the pars tensa, pars flaccida of the TM. En bloc slide speci-
mens were collected and dried on poly-L-lysine coated slides.
Immunohistochemical staining
Sections were deparaffinized with xylene and rehydrated
by serial alcohol solutions. The samples were then processed
by the avidin-biotin-immunoperoxidase complex method.
Antibodies were visualized by 3,3′ -diaminobenzidine tetrahy-
drochloride solution containing 0.3% hydrogen peroxide.
The following antisera were used to identify CK changes:
anti-pan CK (mixture of monoclonal antibodies to CK 1, 4,
5, 6, 8, 10, 13, 18, and 19, Sigma Co., St. Louis, MO, U.S.A.),
K 8.60 (monoclonal antibody to CK10, 11, and weakly CK
1, Sigma Co.), D5/16 (monoclonal antibody to CK5 and 6,
Boeringer-Mannheim, Germany), 6B10 (monoclonal anti-
body to CK 4, ICN, Costa Mesa, CA, U.S.A.), and K 8.12
(monoclonal antibody to CK 13 and 16, Sigma Co.). Nega-
tive controls were prepared by substituting the primary anti-
bodies with normal sera. Since specific antibodies to gerbilline
cytokeratins are not available, the antibodies used were com-
mercially available bovine and human antibodies: (anti-CK1/
10 and anti-CK 13/16 to bovine immunogens, anti-CK4 and
anti-CK5/6 to human immunogens). 
Densitometry
From each ear, data were collected from ten epithelial sites:
cartilaginous, bony and annulus part of the upper and lower
EAC (6 sites), pars flaccida, central and peripheral parts of
pars tensa (3 sites) of the TM, and the middle ear (1 site). In
the cartilaginous part of the EAC, data were collected from
three separate layers of the epithelia: upper and lower supra-
basal, and basal. In the bony and annular part of the EAC,
and the pars flaccida of the TM, data were from two separate
layers: suprabasal and basal. The intensity of immunostainings
was measured quantitatively by video imaging densitometry.
All videomicrographs (Olympus
�) IMT-2, Burlingam, CA;
mti
� TV 70 series camera, Michigan City, IN, U.S.A.) were
recorded directly from tissue sections to an optical disk (Pana-
sonic
�), TQ-2028F, Secacus, NJ, U.S.A.). Recorded images
were played back and captured by Targa
� M8 video-board
(Truevision Inc, Indianapolis, IN, U.S.A.). The intensities
were measured using Java
� histomorphometric software (Jan-
del Scientific, Corte Madera, CA, U.S.A.). A control image
of the optical path was subtracted from each image just before
measurements were done. Five successive measurements were
repeated at each site. Data were then transferred into a spread-
sheet (QuatroPro
�), and statistically analysed by ANOVA and
Fisher's LSD test, using NCSS
� statistical analysis program
(version 5.0). 
RESULTS
Experimental cholesteatomas were divided into five groups
according to the stage of cholesteatoma (11, 12); control (n=
28), stage I (n=7), stage II (n=16), stage III (n=3), and stage
IV (n=2). The results of CK expression throughout the study
are summarized in Table 1.
Pan-Cytokeratin
Pan-CK expression was normally seen in the whole layers
of squamous epithelia of the EAC and the TM, although the
intensity of expression was higher in the suprabasal layer than
in the basal layer. Following cholesteatoma formation, the
expression patterns were changed: (1) the expression of the
suprabasal layers in the lower cartilaginous EAC decreased
in stage II and the expression of the bony EAC decreased in
stages I cholesteatoma; (2) the expression in the pars tensa of
the TM increased in stages II and III cholesteatoma (Fig. 1).
Cytokeratin 4
CK4 was occasionally expressed in the suprabasal epithe-
lial layers of normal specimen. The expression in the lower
annulus of the EAC and the pars tensa of the TM increased
in stages II and III cholesteatoma (Fig. 2). 
Cytokeratin 5/6 
CK5/6 was normally expressed in the basal layers of the EAC
and pars flaccida of the TM. This pattern was not changed
but the intensity of expression in the peripheral part of pars
tensa increased in stages I and II cholesteatoma (Fig. 3, 5).Cytokeratins in Cholesteatoma 383
Cytokeratin 1/10
CK1/10 was normally localized in the suprabasal epithelial
layers of the EAC and the pars flaccida of the TM. The inten-
sity in the suprabasal layers of the lower annulus, and in the
peripheral part of pars tensa increased in stage II cholesteatoma
(Fig. 3).
Cytokeratin 13/16
In normal specimens, CK13/16 was expressed in the basal
epithelial layer of the EAC (Fig. 6A). However, in stages I
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Fig. 1. The intensity scores of cytokeratin immuno-staining were
plotted over the stage of cholesteatoma. Mean data for each
cytokeratin and each site were presented. Asterisks represent
the intensity scores with statistically significant differences from
those of the control group (*p<0.05, ANOVA and Fisher's LSD).
The staining intensity of pan CK is decreasing in the cartilaginous
EAC of stage II and the bony EAC of stage I, but is increasing in
the pars tensa of stage II and III cholesteatoma. 
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Fig. 2. The intensity scores of cytokeratin immuno-staining were
plotted over the stage of cholesteatoma (*p<0.05). CK4 is increas-
ing in the annular EAC, and the pars tensa of stage II and III.
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Fig. 3. The intensity scores of cytokeratin immuno-staining were
plotted over the stage of cholesteatoma (*p<0.05).  CK5 is increas-
ing only in the pars tensa of stage I and II, while CK10 is increas-
ing in the suprabasal layer of the annulus and in the pars tensa
of stage II. 
*
*
*
*
I
N
T
E
N
S
I
T
Y
120
100
80
60
40
20
0
CONTROL I II III IV
low. cart.; basal
upp. annulus; basal
upp. cart.; basal
upp. cart.; upp. suprabasal
pars tensa; periphery
STAGE
CK13/16
Fig. 4. The intensity scores of cytokeratin immuno-staining were
plotted over the stage of cholesteatoma (*p<0.05). CK13/16 is
increasing in the suprabasal layer of the EAC of stage I through
III, and in the pars tensa of stage II and III. In contrast, it is decreas-
ing in the basal layer of the EAC of stage II and in the annulus of
stage III. 
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through III cholesteatoma, it was seen in the suprabasal layer
of the EAC. A transition of expression from basal to suprabasal
layer was occasionally seen in cholesteatoma epithelia (Fig.
6B). Interestingly, the expression pattern seemed to be back
to normal in stage IV cholesteatoma. In contrast, the intensity
of expression in the peripheral pars tensa of the TM increased
throughout the stages (Fig. 4).
DISCUSSION
The patterns of cytokeratin (CK) expression correlate well
with the state of keratinocyte proliferation, migration, and
differentiation. These patterns are known to be affected during
the formation of aural cholesteatoma. In the present study,
gerbilline cholesteatomas of canal ligation (ECL) type were
classified by the extent, i.e., the stage of cholesteatoma (11,
Fig. 5. Representative figures of cytokeratin immuno-staining in control and cholesteatoma tissues. ×200. A. CK5/6 is not expressed
in the pars tensa of normal tympanic membrane. B. CK5/6 is intensely stained in the same site in cholesteatoma. 
A B
Fig. 6. A. CK13/16 is stained in basal layer of the cartilaginous canal in normal specimen. B. Transition of CK13/16 expression from basal
to suprabasal layer is noticed in the same cholesteatoma tissue. Basal on the left, and suprabasal on the right of the photograph. 
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12). CK4 was considered to be a marker of non-keratinizing
squamous epithelium, CK5/6 a marker of basal keratinocytes
and hyperproliferation, CK1/10 a marker of differentiation
or keratinization of squamous epithelium, and CK13/16 and
CONTROL External   upp. cart. 13 13
(N=29) ear canal upp. bony
upp. annl. 13
low. cart. 13 pan
low. bony pan
low. annl. 4,10
TM p. flaccida
p. tensa ctr Pan, 4
P. tensa peri pan, 4, 5, 10, 13
Middle ear mucosa
STAGE I External upp. cart. -- 13↑
(N=7) ear canal upp. bony -- -
upp. annl. -- -
low. cart. -- -
low. bony -- pan↓
low. annl. -- -
TM p. flaccida -- -
p. tensa ctr -- -
P. tensa peri 5↑ --
Middle ear mucosa -- -
STAGE II External upp. cart. 13↓- 13↑
(N=18) ear canal upp. bony -- -
upp. annl. 13↓- -
low. cart. 13↓- pan↓
low. bony -- -
low. annl. -- 4↑, 10↑
TM p. flaccida -- -
p. tensa ctr pan↑, 4↑ --
P. tensa peri pan↑, 4↑, 5↑, 10↑, 13↑- -
Middle ear mucosa -- -
STAGE III External upp. cart. -- 13↑
(N=2) ear canal upp. bony -- -
upp. annl. -- -
low. cart. -- -
low. bony -- -
low. annl. -- 4↑
TM p. flaccida -- -
p. tensa ctr pan↑, 4↑ --
P. tensa peri 4↑, 10↑, 13↑ --
Middle ear mucosa -- -
STAGE IV External upp. cart. -- -
(N=2) ear canal upp. bony -- -
upp. annl. -- -
low. cart. -- -
low. bony -- -
low. annl. -- -
TM p. flaccida -- -
p. tensa ctr -- -
P. tensa peri 5↑, 10↑ --
Middle ear mucosa -- -
Site Basal Lower suprabasal Upper suprabasal
Table 1. The change of cytokeratin expression at various epithelial sites according to the stage of cholesteatoma
Up/down arrows indicate the significant increase/decrease;  “-" marks indicate no change of cytokeratin expression from the control group (p<0.05,
ANOVA and Fisher's LSD). upp.: upper; low.: lower; cart.: cartilaginous; annl:annulus; p.: pars; ctr: center; peri: periphery; pan: panCK; 4: CK4; 5: CK
5/6; 10: CK1/10; 13: CK13/16.386 H.-J. Kim, S.P. Tinling, R.A. Chole
CK5/6 markers of basal keratinocytes and hyperproliferation
(Table 2).
Pan-CK polyclonal antibody is normally expressed in all
epithelial tissues. In the present study, the staining intensity
of pan-CK was weaker in the basal layer of the epithelium in
the EAC in the normal specimen than in the suprabasal layer.
This phenomenon has been partially explained by some inves-
tigators advocating that some antigenic determinants are
masked in situ in certain cell layers, especially if polyclonal
antibodies are used (13). With cholesteatoma formation, pan-
CK expression appeared to be less intense in the suprabasal
layers of the EAC, but it became more intense in the pars tensa
of the TM. This finding suggested that different patterns of
CK expression might exist separately in the EAC and the TM.
Hence, immunohistochemical data collected from a single
part of disease or in an uncertain time frame of the disease
should be cautiously interpreted because they might be mis-
leading. It is still unclear whether the different patterns of
expression represent actually qualitative changes or simply
uneven distributions of CK.
Previously, we found that epithelial hyperplasia in experi-
mental cholesteatoma was more prominent in the early stage
than in the advanced stage (11). These findings suggested
that the epithelial expression of CK in cholesteatoma might
be accordingly different in various clinical stages of the disease.
The results of the present study also show that the expression
patterns of each CK differed with respect to location and se-
verity of the disease and support the concept that some ker-
atinocytes in cholesteatomas show an increased proliferation.
CK 5 and 6 are found in epidermis and hair follicles and
are closely related to each other as judged from peptide maps
(1); these CK are found in proliferating epidermis and hair
follicles. The results of this study show that the expression of
CK 5/6 increased in the pars tensa of cholesteatoma, compared
to controls. Increased CK5/6 expression in the pars tensa of
developing cholesteatomas might be an indication of basal cell
hyperproliferation, which supports the basal cell hyperplasia
hypothesis for cholesteatoma pathogenesis.
Both CK6 and 16 may represent markers for hyperprolif-
erative keratinocytes in general (4, 7). In various epidermal
diseases, there is a reciprocal expression of the keratin mark-
ers for hyperproliferation and keratinization, supporting the
mutual exclusiveness of the cellular events (9, 10). At the
margin of the active psoriatic lesions, the suprabasal K1.12
(CK 13, 16) binding was the earliest change found in the
epidermis (14). In the present study, an increase of CK13/16
expression was also found in the pars tensa of the TM, sug-
gesting that a hyperproliferative process might be present at
this epithelial site during cholesteatoma formation. Therefore
the increased expression of CK5/6 and CK13/16 in the pars
tensa of cholesteatomas suggests that hyperproliferation of
keratinocytes within the cholesteatoma may lead to further
advancement of the cholesteatoma and adds support to the
basal cell hyperplasia theories of cholesteatoma formation. 
Although CK4 and CK13 were usually expressed in the
non-keratinizing epithelia in oral mucosa (9, 10, 15, 16),
CK4 and13 have been demonstrated in some matrices of
cholesteatoma indicating disturbances in the terminal differ-
entiation. In the present study, CK4 expression in the annular
part of the EAC and the pars tensa of the TM revealed a sig-
nificant increase. This result indicated that CK4 expression,
as a marker of disturbances in keratinocyte differentiation,
increased in the deepest meatus and the TM. This finding
suggests that qualitative changes in keratinocytes of chole-
steatoma were generated at the areas of most rapidly expand-
ing part in cholesteatoma. Together with the findings of
keratinocyte proliferation described above, this finding might
also support epidermal migration theory of cholesteatoma
pathogenesis.
CK5 and CK14 are synthesized in the basal epithelial cells,
and are used as markers of keratinizing squamous epithelium
(1, 2, 3, 18). The presence of this pair of CK was detected in
human cholesteatoma tissue by using SDS-PAGE (6). The
epidermis of cartilaginous part showed a normal skin type
differentiation, characterized by expression of CK5/14 in the
basal layer, and CK10 in the suprabasal layer. The existence
of this paired CK in the specimens of human middle ear
cholesteatoma strongly favors the migration theory in the
genesis of cholesteatoma, as Broekaert et al. mentioned (3).
Some authors have designated the cholesteatoma tissue as
type A and type B according to the presence of CK13 and
CK16. The suprabasal layer was selectively stained in type A,
whereas the basal layer was stained in type B. They suggested
that type A is an extension of meatal skin, which has retract-
ed to the middle ear cavity, and type B is the cholesteatoma
tissue itself. They further hypothesized that cholesteatoma
may be composed of epithelium that has transformed from
type A (near the external canal) to type B during cholesteatoma
growth (7). In the present study, those CK were normally
expressed in the basal epithelial layer; in contrast, they were
also expressed in the suprabasal layer of the cholesteatomatous
epithelium. Surprisingly, there was an area with a transitional
expression pattern from the basal to suprabasal layer in some
specimens. Some authors have argued that the deeper part of
the EAC might be the areas of proliferation from studies of
CK6 and 16 expressions. However, others believed that the
presence of CK6 and 16 in the deep meatal skin would be
related to a specific migration process (14). In the present
PanCK All epithelia
CK1/10 Cornification and terminal differentiation
CK4 Non-cornyfying epithelium
CK5/6 Hyperproliferation of basal keratinocytes
CK13/16 Hyperproliferation and terminal differentiation
Cytokeratin                   Associated with
Table 2. Epithelial characteristics associated with tested
cytokeratinsCytokeratins in Cholesteatoma 387
study, the increased CK13/16 expression was found in the pars
tensa of the TM and the suprabasal layer of the deeper EAC.
This result may suggest that proliferation of keratinocytes
result in an increased migration at the most rapidly expanding
epithelial site of cholesteatoma.
Cytokeratin expression has been noted to correspond to the
extent of differentiation within keratinocytes. More highly
differentiated keratinocytes express CK1/CK10, whereas the
non-keratinizing epithelia in oral mucosa express CK4/CK13.
In the present study, we observed an increase in both CK4
and CK10 with advancing cholesteatomas. CK4 expression
was seen to increase in the suprabasal layer of the epithelium
of the EAC as the cholesteatomas advanced in size. Other
investigators observed an increased CK4/13 expression in
some matrices of cholesteatoma indicating disturbances in the
terminal differentiation (14, 17, 18).
CK1 and CK10 are synthesized in the suprabasal layer and
are recognized as markers of increased differentiation or corni-
fication of the squamous epithelium. In the present study, we
observed an increased CK10 expression in the suprabasal layer
near the annulus and the peripheral pars tensa in cholestea-
tomas. Some authors have demonstrated a decrease of the
CK10 expression in cholesteatoma and proposed that the
terminal keratinization might have been inhibited by the
diseased state (3, 8, 19). These results seem somewhat con-
tradictory, but it may be due to the different methods of
sampling and analysis. Previous studies (3, 6, 8, 19) did not
describe which portion of cholesteatoma had been collected,
nor how advanced their cholesteatomas were. On the other
hand, in the present study, immuno-expression data were
collected from defined areas of the cholesteatoma in different
stages of the disease. Our results suggest that CK10 expression
may be affected by the extent of cholesteatoma and the severi-
ty of disease. Cytokeratin expression in these experimental
cholesteatomas appear to indicate that at certain sites within a
cholesteatoma some keratinocytes may differentiate into
highly keratinizing cells (CK10), while others appear to resem-
ble less differentiated keratinocytes (CK4), possibly indicating
some defects in the control of keratinocyte differentiation.
Finally, the interpretation of these data must be tempered
by the possibility that gerbil cytokeratin may not share the
exact antigenic characteristics of murine and human keratin
and the antibodies used in this study.
In summary, the findings of this study support the concept
that the normal keratinizing epithelium of the TM undergoes
changes, as it forms a cholesteatoma in the external canal and
middle ear. Our finding of increased CK5/6 and CK13/16
expression provides further evidence that the epithelium with-
in cholesteatoma shows increased proliferation of keratinocytes,
especially of the pars tensa near the malleus. Another evidence
for hyperproliferation is based on increased rates of cell divi-
sion (20) and increased expression of proliferating cell nuclear
antigen (PCNA) (21). This proliferation also appears to be
associated with increased keratinocyte migration. The increased
CK4 expression in the deepest meatus near the TM and the
transition of CK13/16 expression from basal to suprabasal
layer suggested that the epithelial migration might be in-
creased from lateral to medial portion within the auditory
canal. The result of increased CK4 and CK1/10 expression
might suggest an alteration of terminal differentiation in
cholesteatoma pathogenesis.
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